Background: The availability and affordability of safe, effective, high-quality, affordable anticancer therapies are a core requirement for effective national cancer control plans.
Introduction
The General Assembly of the United Nations, in its 2011 Political Declaration on the prevention and control of noncommunicable diseases [1] , highlighted the primary role and responsibility of governments in improving access and affordability to high-quality medicines. Indeed, in a controversial step, it has even encouraged the full use of trade-related aspects of intellectual property rights (TRIPS) flexibilities, including compulsory licensing, to achieve this end if necessary. Furthermore, in its Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013 to 2020, the World Health Assembly [2] has set a target of an 80% availability of affordable basic technologies and essential medicines required to treat major non-communicable diseases including cancer. Within cancer care and national cancer control planning, medicines play an essential core role, along with surgery and radiotherapy, in both cure and palliation. Endorsed and promoted by ESMO and the Union for International Cancer Control among others, this approach was emphasised in the very recent 70th World Health Assembly resolution on cancer prevention and control [3] .
The World Health Organisation defines essential medicines as those that 'satisfy the priority health care needs of the population which they are intended to be available in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and community can afford' [4, 5] . In 2015, the WHO made the largest update of its Model List of Essential Medicines for cancer since its inception in 1977 [5] .
The European Society for Medical Oncology's 2020 vision statement recognises that progress in the management of cancer care can and will only occur when high-quality care is both available and affordable to everyone everywhere [6] . This concern underscores the impetus for the previous ESMO study to evaluate the availability, out-of-pocket costs and accessibility of anticancer medications in Europe [7] , which highlighted dramatic disparities of access particularly to new and expensive anticancer medications between the wealthier countries of Western Europe and the developing economies of Eastern Europe. Similar concerns also drove the development of the ESMO-led Global Opioid Policy Initiative (GOPI) studies evaluating the availability outof-pocket costs and regulatory barriers impeding access of cancer patients to opioid medications for the relief of moderate and severe cancer pain [8] [9] [10] [11] [12] [13] . Building on these validated approaches to public policy surveys, this study extends geographic coverage to further inform about the current state of global oncology regarding the availability and affordability of cancer medicines.
The primary aims of the study were to evaluate (i) the formulary availability of licensed antineoplastic medicines in the countries of the world outside of Europe, (ii) patient out-of-pocket costs for the medications, (iii) the actual availability of the medication for a patient with a valid prescription, (iv) information relating to possible factors adversely impacting the availability of antineoplastic agents and (v) the impact of the country's level of economic development on these parameters.
Methods

Project development
The study was developed by the ESMO Global Policy Committee, with input and cooperation of the ESMO Executive Board, ESMO National Representatives and other ESMO committees, including those covering EU Policy, Education, Practising Oncologists, as well as the ESMO Faculty and three collaborating partners: the Union for International Cancer Control, the Institute of Cancer Policy of King's College London and the European Society of Oncology Pharmacy (ESOP). Implementation and data analysis was carried out by independent researchers from the collaborating partner organisations. The World Health Organization (WHO) was a supporting partner in this project as part of an ongoing 3-year work plan between WHO and ESMO, who enjoys 'official relations status' with WHO.
Study format and data collection
The questionnaire-based survey tool was modelled on the previous ESMO study of the availability and accessibility of anticancer medicines in Europe [7] .
The survey consisted of three parts: part 1 consisted of six general questions regarding the country's healthcare system; part 2 surveyed the formulary of generic anticancer medication commonly used over a wide range of cancers, and part 3 surveyed the formulary of generic anticancer medication used in seven highincidence cancers (Table 1) .
The list of anticancer medications for each disease entity was derived from ESMO and National Comprehensive Cancer Network (NCCN) guidelines as well as 'UpToDate' subject reviews, where medicines approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) as of March 2015 were included. The list was edited for relevance by the ESMO Global Policy Committee.
Field reporters were asked to indicate the following for each medication: whether it was permissible to prescribe the cancer medicine for the stated indication; if the medication costs are reimbursed for this indication; the average proportion of the full retail price patients are obliged to pay out-of-pocket for the medication; the actual availability of the medication for most patients in the country when prescribed and in cases where the medication is not always available, the dominant reason for lack of availability.
ESMO and the collaborating partners sought to identify a minimum of two field reporters, either oncologists or oncology pharmacists, through an iterative process for each country. The field reporters were derived from either national or approved representatives of the professional organisations collaborating in this project. A total of 304 field reporters from 97 countries were invited to participate. Repeat requests for data submission were sent to non-responding invitees to minimise the number of countries where data was not verifiable between two or more reporters.
Electronic survey forms were developed on a Qualtrics survey software platform which facilitated automatic data entry into an Excel spread sheet for analysis. Data submitted between 30 April and 18 December 2015 by the two field reporters from each country were cross-checked by the principle investigator (Nathan Cherny). When discrepancies between reporters were identified, clarifications were requested. When discrepancies persisted, priority was given to the response provided by the most highly credentialed reporter and where supportive data were presented. The principle investigator tabulated and graphically presented the data in the format used in the previous ESMO survey for Europe [7] .
Data regarding medications with relatively recent marketing approval and not included in the 2015 WHO Model List of Essential Medicines, were cross-referenced with scores derived from the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) using the revised version 1.1 of the scale [14] .
The results pertaining to study aims 1 and 2 are presented in figures labelled 'Formulary availability and out-of-pocket cost'. These colour-coded figures indicate (in black) medications that are not on formulary (aim 1), and for medicines on formulary (other colours), indicate the percentage of the full price that patients pay out-of-pocket after state or insurance reimbursement (aim 2). The results pertaining to aim 3, actual availability of the medication for a patient with a valid prescription are presented in figures labelled 'Actual availability'. These colour-coded figures indicate (in black) medications that are not on formulary, and for medicines on formulary (other colours), indicate the percentage of instances in which a patient with a valid prescription can actually access the prescribed medication.
The preliminary data were posted on the ESMO website for external validation between 16 March and 31 May 2016. Invitations were sent to all members of the coordinating and collaborating partner organisations to review the data and to submit any corrections or amendments. Amendments and corrections were collated, cross-checked and incorporated into the final report.
The country data are stratified according to the level of each country's economic development based on World Bank Criteria (http://data.worldbank.org/country) classifying them as high income (high), upper middle income, lower middle income and low-income (low) and are presented alphabetically. For clarity of presentation, and to highlight findings of inequity and impact, this report focuses on medications included in the World Health Organization's Model List of Essential Medicines [5] and recently approved medications with an ESMO-MCBS score >2 (corresponding to moderate to high level of clinical benefit) [14] .
Results
Surveys were submitted by 135 individual reporters from 63 countries (Tables 2 and 3 ). Additional data following peer review were submitted by a further 54 reporters from 19 countries.
Medications included in the World Health Organization's 2015 Model List of Essential Medicines
The antineoplastic medicines chapter of the WHO's Model List of Essential Medicines was updated in April 2015 [5] following comprehensive review. The WHO updated the list adding 16 new medicines such as capecitabine (for colorectal and breast cancer), oxaliplatin (for adjuvant and metastatic colorectal cancer), irinotecan (for metastatic colorectal cancer), vinorelbine (for nonsmall-cell lung cancer and metastatic breast cancer), anastrozole (for adjuvant and metastatic breast cancer) and two very highcost medications, which at that time were still under patent protection: imatinib (for GIST tumours) and trastuzumab (for adjuvant and metastatic HER2 overexpressed breast cancer).
In high-income and in upper middle-income countries, most of the medicines incorporated into the WHO Model List of Essential Medicines are on formulary and are available to patients at either no cost or on a subsidised basis ( Figure 1 ). Overall in low-middle-income and in low-income countries reports of poor accessibility are greater, and in many countries, patients incur full Problems with the accessibility of medicines were reported substantially more prevalent in middle-income and low-income countries ( Figure 2 ): in particular in Colombia, Iraq, Malaysia, Suriname El Salvador, Kenya, Sudan Afghanistan, Burkina Faso, Haiti, Malawi, Nepal, Tanzania, Uganda and Zimbabwe. The dominant reported barriers to accessibility were either a lack of or unreliable supplier, or budgetary restraint (Figure 3) . Lack of commercial motive and manufacturing problems was less commonly reported.
Approved medications not on the WHO Model List of Essential Medicines, with ESMO-MCBS score >2
At the time we did the survey, 19 medications from 7 disease groups met these criteria; lapatinib, pertuzumab and TDM-1 (breast cancer); erlotinib, gefitinib, afatinib (EGFR-mutated non-small-cell lung cancer), crizotinib (ALK translocated nonsmall-cell lung cancer); cetuximab and panitumumab (RAS/RAF wild-type metastatic colorectal cancer); sunitinib, pazopanib, axitinib, sorafenib, everolimus and temsirolimus (renal cell cancer); ipilimumab and vemurafenib (melanoma) and abiraterone and enzalutamide (prostate cancer).
In most middle-and low-income countries, with few exceptions (Brazil, Colombia and Turkey), these medications not on the WHO EML are very infrequently available at reduced cost to patients and many of them were not available at all. High out-ofpocket costs were less frequent in high-income countries where the medications were almost always on formulary (Figure 4 ). Overall accessibility of these agents was less than for medications included in the WHO EML, and problems of accessibility were greater in lower-middle and low-income countries (Table 5) . Even in high-income countries, limited accessibility was sporadically reported and was most frequently reported in Chile, Cyprus Saudi Arabia, Uruguay and Venezuela ( Figure 5 ).
The dominant reported barriers to accessibility to cancer medicines were budgetary constraints as well as unreliable supply. The dominant reported barrier in high-income and upper middleincome countries was budgetary constraints, while in lower middle-income and low-income countries, lack of supplier or commercial motivation was increasingly dominant. Parallel export, whereby shortages are caused by the export of relatively inexpensive medications for foreign use, was infrequently reported as a major cause of lack of accessibility; however, it was reported in South Korea, Qatar, Venezuela, Iran and Mexico ( Figure 6 ).
Full tabular reports
The full tabular reports for widely used generic medications and for the seven disease-related indications are presented in the supplementary Excel File, available at Annals of Oncology online.
Discussion
The are several major findings of this study. First, and of greatest concern, is the finding that for cancer patients and their families in low-middle-and low-income countries of the world, many anticancer medications recommended on the WHO's Model List of Essential Medicines are available only at full cost as an out-ofpocket expense, and that accessibility is limited because of unreliable supply. Second, many of the recently approved agents in the treatment of metastatic cancers are often unavailable or available only again at great personal expense in countries other than those which are most economically developed. This contributes to profound inequity in access to treatment and care of patients with for example, EGFR-mutated non-small-cell lung cancer, renal cell cancer, melanoma, RAS/RAF wild-type metastatic colon cancer, castrate-resistant prostate cancer and Her-2 amplified metastatic breast cancer.
These findings are consistent with those of the previous International Consortium study evaluating the formulary availability, out-of-pocket costs and accessibility of anticancer medication in Europe, which demonstrated similar patterns of availability and accessibility between the high-income countries of Western Europe compared with the upper middle-income countries of Eastern Europe [7] . Significantly, the European study did not include any low-middle-or low-income countries [7] , and it is in these severely economically challenged countries that the greatest discrepancies in access occur.
The discrepancies in access to cancer care and major discrepancies in cancer outcomes between rich and poor countries are well recognised and described [15, 16] . Recent trends suggest that this divide is widening: there is evidence that the prevalence and mortality of cancer in high-income countries are declining, while in poor countries they are increasing [15, [17] [18] [19] . The Global Task Force On Expanded Access To Cancer Care And Control [17] reported that only 5% of global resources for cancer care are spent in the developing world despite having almost 80% of disabilityadjusted life years lost to cancer globally.
The cancer burden and mortality of the economically disadvantaged countries of the world is disproportionate [15] [16] [17] 20] for a range of reasons. Cancer prevention and early detection programs are weak [17] [18] [19] , there is a high and rising prevalence of tobacco smoking [21] , a rising incidence of obesity [22] , and low immunisation rates and viral infections such as hepatitis and human papilloma virus account for 20%-30% of cancer deaths [18] . A range of social determinants mean that most patients who 
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Annals of Oncology present to conventional cancer care (many never make it this far) do so with advanced disease [15, 16, 20] . For those patients who do present with potentially curable disease, the situation is further confounded by poor clinical governance and quality of care, the lack of general financing for healthcare, and low levels of health insurance or social security coverage [23] . The ability to provide care is further impeded by well recognised deficits in pathology [24] , radiotherapy [25] and surgery [26] reflecting a systems-wide failure to deliver on or develop comprehensive national cancer control plans. Finally, all of these discrepancies are further exacerbated by the rising cost of both old and new cancer medicines [27] . High out-of-pocket costs for treatments are a key limitation to accessing health services. Even in high-income countries, high co-payments for expensive anticancer medication are a major cause of personal bankruptcy [28] [29] [30] [31] and in low-income countries often there is little financial risk protection because costs are largely borne by households themselves rather than by governments or insurance schemes [31] [32] [33] [34] [35] [36] . On average, almost 50% of health care financing in low-income countries comes from outof-pocket payments, as compared with 30% in middle-income countries, and 14% in high-income countries. [23, 31, 35] . For patients and for their families, this is often catastrophic, because care is either unaffordable or, when paid for from personal finances, pushes many into poverty from medical expenses, particularly when this is combined with a loss of income due to illhealth [20, 33, 34, 37] .
International public policy initiatives to improve access to affordable medications
There have been many aspirational initiatives to address this issue. The 2011 Political Declaration of the High-level Meeting of the UN General Assembly on the Prevention and Control of Non-communicable Diseases [1] declared that the global burden and threat of non-communicable diseases including cancer is a major concern which undermines social and economic development. It highlighted the primary role and responsibility of Governments in these issues. This UN document repeatedly highlighted the issue of affordability of medical technologies and even endorsed 'the full use of trade-related aspects of intellectual property rights (TRIPS) flexibilities'. Property Rights (TRIPS) [38] [39] [40] [41] [42] .
The WHO has emphasised that provision of adequate financial protection from the costs of seeking and using medical care is a critical marker of the effectiveness of a healthcare system [43] and has encouraged its Member States to provide universal health coverage in some form [35] as a means to promote the human right to health [44] . The United Nations passed a declaration that calls for universal access to health care that does not cause financial hardship [45] and has further reiterated the goal of universal health coverage under goal number 3 (good health and wellbeing) of the UN's 2030 Sustainable Development Goals [46] . More recently, the World Health Assembly (WHA), the governing body of the WHO, passed a landmark resolution on Cancer prevention and control [3] , representing a big step forward in the awareness and acceptance of the need for immediate action from all UN Member States to take concrete actions on cancer control. While the 2011 UN Political Declaration emphasised prevention, the 2017 Cancer Resolution calls on Member States to ensure a comprehensive approach through national cancer control plans, to assure cancer registries gather complete and accurate data, and most importantly, to provide access to cancer services, including timely access to cancer medicines, vaccines and medical devices, and to optimise their oncology workforce [3] .
ESMO has been continuously active in these areas and has contributed to the updates of the WHO EML model list [5] , and the 2017 WHO list of priority medical devices for cancer management [47] that highlights, for the most frequent tumour types, the specific medical devices necessary for the delivery of adequate care. To fulfil the call of the 2017 Cancer Resolution, WHO is developing an oncology workforce study in collaboration with ESMO's Global Policy Committee. The study will include a survey which will match the list of necessary cancer interventions to professional competencies required to deliver them, accompanied by a modelling tool to estimate future workforce requirements [48] .
The WHO's Model List of Essential Medicines is a guide for the development of national and institutional essential medicine lists that was developed with the aim of promoting equity in health. The WHO defines essential medicines are those 'that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford' [4] . One of the voluntary aims of the World Health Assembly Global Action Plan for the Prevention And Control Of Noncommunicable Diseases 2013-2020 includes the aim [2] to achieve an 80% availability of the WHO basic technologies and essential medicines, including generics, required to treat major noncommunicable diseases in both public and private facilities. With regard to anticancer medications, this ESMO study indicates that the international community is still far from achieving this goal. Indeed delivering better outcomes with affordable cancer medicines requires significant cancer systems and health care delivery improvements in many countries in fundamental Actual availability (accessibility with valid prescription). areas-such as detecting cancer at the earliest possible stage, and the provision of high-quality basic surgical and medical services.
Learning from positive experiences
Among the low-middle-income and low-income countries, some stand out as exceptions in managing to provide essential anticancer medicines at affordable prices as a part of developing broad cancer care systems; examples include Egypt, El Salvador, Indonesia, Malawi, Palestine, Sudan, Uganda, Vietnam and Zambia (Table 1) . These data, if sustained by confirmatory studies, suggest that there may be salient models in governance and public health administration to be derived from the experience of these low-middle-and low-income countries that are politically committed to addressing affordable, equitable and safe cancer care, including the provision of cancer medicines.
Disclaimers
The information presented in this survey is a time-constrained 'snapshot' of the situation, as was reported during the survey period, and it will be subject to change over time. Consequently this dataset does not incorporate newer immunotherapies that were introduced to the therapeutic repertoire since the study was designed and administered. The data were derived from practicing clinicians and oncology pharmacists working in the field and not from state authorities or statutory bodies. Reporting physicians were asked to consult with regulatory authorities in circumstances in which they were unsure of cost or a formulary issue. The accuracy of the data is dependent on the reporting accuracy of field reporters and their due diligence in verification of facts. Field reporters were nominated on the basis of recognised involvement in oncology practice and, in many cases, in leadership positions in oncology or in oncology pharmacy in their country.
When submitted responses were incomplete, submitted data were entered and items not addressed were marked as missing data. In the dataset for medicines on the WHO Model List of Essential Medicines there were no missing data. In the dataset for new medications with an ESMO-MCBS score >2, missing data rates varied between the national income groups: high income 4%, upper middle income 21%, low middle income 1%, low income 11%.
The methodology used in this study incorporated measures to minimise error, including multiple reporters, cross-checks between reporters, and a process of open peer review. Crosschecking between reporters was not possible in 26 countries where submissions were received by only one reporter, in which case additional verification was only possible in the open peerreview process.
In summary, this study finds that there are disparities in the formulary availability, out-of-pocket costs to patients, and actual availability for many anticancer medicines particularly in middle-and low-income countries of the world. In low-middleincome and low-income countries these discrepancies are profound even for anticancer medicines included in the WHO Model List of Essential Medicines. Discrepancies are most severe in incurable diseases where gains in improved patient outcomes are dependent on the availability of expensive anticancer agents for which major differences were seen in availability and in outof-pocket costs of in all but the very wealthiest countries in the world.
